Keyphrases
Primary Sjögren's Syndrome
100%
Placebo-controlled
50%
Salivary Gland Ultrasonography
50%
Randomized Double-blind
50%
Abatacept
50%
Phase II Trial
50%
Single Center
50%
Clinical Phenotyping
50%
Primary Sjgren's Syndrome
22%
European League against Rheumatism (EULAR)
17%
Serious Adverse Events
16%
Placebo
16%
Placebo Groups
16%
ESSDAI
16%
Sjögren's Syndrome
15%
Disease Activity
13%
Patient-Reported Outcomes Measurement Information System (PROMIS)
11%
Disease Damage
11%
Groningen
11%
Adverse Events
11%
Drug Dosing
11%
Disease Activity Score
9%
Patient Characteristics
7%
Unstimulated Saliva
7%
Clinical Phenotype
7%
Ocular Staining Score
7%
Minor Salivary Gland Biopsy
5%
Biological Characteristics
5%
Costimulation
5%
Systemic Disease
5%
Vaginal Biopsy
5%
Endocervix
5%
Treatment Group
5%
CD45+ Cells
5%
Cervicovaginal Lavage
5%
Vaginal Health Index
5%
Between-group Difference
5%
Sjgren's Syndrome
5%
Pharmacist
5%
Adjusted Means
5%
Disease-modifying Antirheumatic Drugs (DMARDs)
5%
Lost to Follow-up
5%
Clinical Manifestations
5%
Consensus Group
5%
Subcutaneous Injection
5%
University Medical Centre
5%
Standard of Care
5%
Netherlands
5%
Treatment-related
5%
Bristol-Myers Squibb
5%
Medicine and Dentistry
Case-Control Study
50%
Salivary Gland
50%
Vaginal Dryness
50%
Phenotype
50%
Echography
50%
Sjoegren Syndrome
50%
Biopsy
28%
Leukocyte
25%
Disease
19%
Clinical Study
12%
Lavage
12%
Lymphatic Endothelium
12%
Premenopause
12%
Erythroblastosis
12%
Endometriosis
12%
Oncogene
12%
Podoplanin
12%
Caldesmon
12%
Flow Cytometry
12%
Endothelial Cell
12%
Lymphocytic Infiltration
12%
B Lymphocyte
12%
Smooth Muscle Cell
12%
Immunoassay
12%
Cervix
12%
Laparoscopy
12%
Vascular Smooth Muscle Cell
12%
Lymphocyte
12%
Rheumatic Disease
11%
Patient-Reported Outcome
11%
Outcome Assessment
11%
Disease Activity
11%
Patient Characteristics
7%
